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Objectives The goal of this study was to examine the relative impact of QRS morphology and duration in echocardiographic
responses to cardiac resynchronization therapy (CRT) and clinical outcomes.
Background At least one-third of all patients treated with CRT fail to derive benefit. Patients without left bundle branch block
(LBBB) or patients with smaller QRS duration (QRSd) respond less or not at all to CRT.
Methods We retrospectively assessed baseline characteristics, clinical and echocardiographic response, and outcomes of
all patients who received CRT at our institution between December 2003 and July 2007. Patients were stratified
into 4 groups according to their baseline QRS morphology and QRSd.
Results A total of 496 patients were included in the study; 216 (43.5%) had LBBB and a QRSd 150 ms, 85 (17.1%)
had LBBB and QRSd 150 ms, 92 (18.5%) had non-LBBB and a QRSd 150 ms, and 103 (20.8%) had non-
LBBB and QRSd 150 ms. Echocardiographic response (change in ejection fraction) was better in patients with
LBBB and QRSd 150 ms (12  12%) than in those with LBBB and QRSd 150 ms (8  10%), non-LBBB and
QRSd 150 ms (5  9%), and non-LBBB and QRSd 150 ms (3  11%) (p  0.0001). In a multivariate step-
wise model with change in ejection fraction as the dependent variable, the presented classification was the
most important independent variable (p  0.0003). Long-term survival was better in LBBB patients with QRSd
150 ms (p  0.02), but this difference was not significant after adjustment for other baseline characteristics
(p  0.15).
Conclusions QRS morphology is a more important baseline electrocardiographic determinant of CRT response than QRSd.
(J Am Coll Cardiol 2012;60:592–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.059In the past decade, cardiac resynchronization therapy
(CRT) has been shown to improve cardiac function and
heart failure symptoms, induce reverse myocardial remod-
eling, enhance quality of life, prevent heart failure admis-
sions, and even prolong survival (1–4). Moreover, with
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VErses Remodeling in Systolic left vEntricular dysfunc-
tion), MADIT-CRT (Multicenter Automatic Defibrillator
Implantation Trial with Cardiac Resynchronization Ther-
apy), and RAFT (Resynchronization-Defibrillation for
Ambulatory Heart Failure Trial), indications are expanding
to less symptomatic patients (5–7). Nevertheless, it is
broadly accepted that 30% to 50% of all patients who fall
under the broad inclusion criteria of randomized controlled
trials do not respond to this therapy (8,9). Improvements in
postimplantation management as well as better patient
selection may potentially decrease the number of so-called
“nonresponders” (10). Regarding patient selection, it has
been noticed that certain subgroups, often underrepresented
in clinical trials, seem to benefit less or not at all from CRT.
Such subgroups include: those of advanced age, males, and
those with ischemic cardiomyopathy, atrial fibrillation,
non–left bundle branch block (LBBB) morphology, and
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August 14, 2012:592–8 CRT Response by QRS Morphology and DurationQRS duration (QRSd) 150 ms (11). However, it is not
clear what the main drivers of nonresponse to CRT are
because many of the aforementioned negative predictors are
interrelated. For example, previous studies demonstrated
that patients with non-LBBB morphologies also have
shorter QRSd, are more likely to be male, and have more
ischemic cardiomyopathy (12). To shed more light on the
interaction between QRS morphology and QRSd, the goal
of the current retrospective study was to determine echocardio-
graphic response and outcome after CRT implantation as strati-
fied according to both baseline electrocardiographic characteristics.
Methods
Study population. We reviewed the medical records of all
patients who received a new CRT device at the Cleveland
Clinic (Cleveland, Ohio) between December 2003 and July
2007. Patients without an available pre-implant electrocar-
diogram (ECG) were excluded. In all other patients, the
morphology of their baseline ECG was assessed and clas-
sified as either LBBB, right bundle branch block (RBBB),
nonspecific intraventricular conduction delay (IVCD),
paced rhythm, or narrow QRS complex. The latter 2
morphology types were not studied further. LBBB was
defined as QRSd120 ms, a monophasic QS or rS complex
in V1, and a monophasic R-wave in V6. RBBB was defined
as QRSd120 ms, a deep terminal S wave in I and V6, and
n RSR prime, wide R, or qR pattern in V1. IVCD was
efined as QRSd 120 ms not meeting criteria for either
BBB or RBBB. Patients with RBBB or IVCD morphol-
gy were grouped as having a non-LBBB morphology.
inally, 4 groups were established by dichotomizing LBBB
nd non-LBBB patients according to the duration of their
RS complex (150 ms or 150 ms). The duration of the
RS complex was automatically computed by using ECG
nalysis software. The medical charts of these patients were
eviewed, and demographic, clinical, electrocardiographic,
chocardiographic, and outcome data were abstracted. This
etrospective study was approved by the institutional review
oard of the Cleveland Clinic.
ata synthesis. The primary endpoint of this study was
he change in ejection fraction (EF). Secondary endpoints
onsisted of changes in other echocardiographic variables
left ventricular end-diastolic diameter [LVEDD], left ven-
ricular end-systolic diameter, mitral regurgitation [MR]),
hanges in New York Heart Association (NYHA) func-
ional class, and a composite clinical endpoint (all-cause
ortality, heart transplantation, or left ventricular assist
evice [LVAD] implantation). Mortality was confirmed by
uerying the U.S. Social Security Death Index. Echocar-
iograms were obtained as clinically indicated and performed
ccording to standard procedures of the echocardiography labo-
atory of the Cleveland Clinic. Interpretation was conducted by
oard-certified cardiologists who were unaware of the current
tudy. MR was graded on a scale of 0 through 9, according to the
003 American Society of Echocardiography guidelines, with 0 cepresenting no MR and 9 repre-
enting 4 MR. Super-responders
ere defined as patients with an
mprovement in EF 20%. Nega-
ive responders were defined as hav-
ng no improvement in EF. For the
urpose of this analysis, the pre-
mplant echocardiogram was the last
ne before implantation and the
ost-implant echocardiogram
when available) was the one closest
o the 1-year follow-up and at least 2
onths after CRT initiation. Simi-
arly, NYHA functional class was
scertained closest to a 1-year
ollow-up period. Medications were
ecorded immediately before im-
lantation of the CRT device.
All implantations were per-
ormed at the Cleveland Clinic.
n the vast majority of patients,
evice implantation was successfully
ccomplished by using a transvenous approach by electro-
hysiologists targeting a lateral or posterolateral vein for the
eft ventricular (LV) lead position. If not, LV lead place-
ent was achieved by a minimally invasive surgical proce-
ure. The CRT devices were programmed at the discretion
f the treating physicians.
tatistical methods. Comparisons between the 4 groups
ere made by using analysis of variance or the Kruskal-
allis test for continuous variables and chi-square test for
iscrete variables. For variables that were significantly dif-
erent among groups, paired comparisons were made to
dentify which groups were different. The Tukey test was
sed for continuous variables and the Fisher exact test with
onferroni correction for discrete variables. A stepwise
ultivariate linear regression model (probability of 0.05 to
nter or leave the model) was constructed to identify
ignificant variables associated with changes in EF after
RT. Kaplan-Meier curves were constructed to compare
urvival for the primary endpoint between the 4 groups. The
og-rank test was used to determine significance. Univariate
nd multivariate Cox proportional hazards regression
odels were constructed to investigate the independent
alue of different baseline characteristics for the primary
ndpoint. Statistical significance was set at a 2-tailed
robability level of 0.05. All statistical analyses were
erformed by using JMP Pro version 9.0 (SAS Institute,
nc., Cary, North Carolina).
esults
total of 812 patients underwent CRT device implantation
etween December 2003 and July 2007. Figure 1 depicts
ow the final 4 groups were assembled. The final study
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
EF  ejection fraction
IVCD  intraventricular
conduction delay
LBBB  left bundle branch
block
LV  left ventricular
LVAD  left ventricular
assist device
LVEDD  left ventricular
end-diastolic diameter
MR  mitral regurgitation
NYHA  New York Heart
Association
RBBB  right bundle
branch block
QRSd  QRS durationohort comprised 496 patients. Of these, 216 (43.5%)
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CRT Response by QRS Morphology and Duration August 14, 2012:592–8patients had LBBB and QRSd 150 ms, 85 (17.1%) had
LBBB and QRSd 150 ms, 92 (18.5%) had non-LBBB
and QRSd 150 ms, and 103 (20.8%) had non-LBBB and
QRSd 150 ms. Patients receiving a CRT device almost
always received the defibrillator function as well (98%, 96%,
98%, and 95%, respectively; p  0.63), and the percentage
of biventricular paced beats was similar between the 4
groups (99 [97 to 100], 99 [96 to 100], 99 [97 to 100], and
99 [95 to 100]; p  0.24). Figure 2 displays the distribution
of QRS width in function of QRS morphology.
Figure 1 Composition of the Study Population
ECG  electrocardiogram; IVCD  intraventricular conduction delay; LBBB  left b
Figure 2 Histogram of QRS Duration in the Study Population
LBBB  left bundle branch block.Baseline characteristics of the 4 groups are listed in Table 1.
Both groups with non-LBBB morphologies were more
likely to have ischemic cardiomyopathy (p  0.001) and
orrespondingly were more likely to be male (p  0.0001)
nd have a history of tobacco use (p  0.009). Patients with
on-LBBB morphologies were also on average 4 years
ounger (p  0.001) and received more antiarrhythmic
rugs (p  0.0005) than those with LBBB morphologies.
here were small differences in baseline EF (p  0.04),
hich were not significantly different between individual
roups when corrected for multiple comparisons. Patients
ith a non-LBBB and QRSd 150 ms had more LV
ilation, both in diastole (p  0.002) and systole (p 
.008), compared with other groups.
A total of 475 (96%) and 323 (65%) had echocardiogram
ata available before and after CRT device implantation,
espectively. Comparisons could be made in 313 (63%) of all
atients. Survival (freedom of combined endpoint) was
orse (p  0.005) in patients without available echocardio-
rams for comparison. Patients without available echocar-
iogram data were also more likely to have non-LBBB and
RSd 150 ms and less likely to have LBBB and QRSd
150 ms (p 0.03). Echocardiograms were performed at a
ean of 12  10 months after CRT implantation. The
mprovement in EF was most pronounced in patients with
BBB and QRSd150 ms (12 12%), followed by LBBB
nd QRSd 150 ms (8  10%), non-LBBB and QRSd
branch block; RBBB  right bundle branch block.undle150 ms (5  9%), and non-LBBB and QRSd 150 ms
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August 14, 2012:592–8 CRT Response by QRS Morphology and Duration(3  11%) (p  0.0001) (Table 2). The same pattern could
e seen for reduction in LVEDD (p  0.007) and left
entricular end-systolic diameter (p  0.0005). When
airwise comparisons were made (with correction for mul-
iple comparisons), the improvement in EF was significantly
igher in patients with LBBB and QRSd 150 ms com-
ared with non-LBBB and 150 ms (p  0.0001) and
on-LBBB and QRSd150 ms (p 0.0009) patients. The
ifference between LBBB patients with QRSd 150 ms or
150 ms approached significance (p  0.12). Moreover,
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
LBBB and
QRSd >150 ms
(n  216)
LB
QRSd
(n
Demographic characteristics
and history
Age (yrs) 71 10 7
Male 61
BMI (kg/m2) 28.5 5.6 28
NYHA functional class 2.9 0.4 2
ICM 53
CABG 34
History of tobacco use 60
History of atrial fibrillation 46
History of hypertension 67
History of hyperlipidemia 56
Renal dysfunction 26
COPD 13
Diabetes mellitus 41
Echocardiography
EF 21 8 2
LVEDD (cm) 6.2 1.0 6
LVESD (cm) 5.2 1.2 4
MR grades (1–9) 3.8 2.4 3
Laboratory
BNP (pg/ml) 561 808 50
Creatinine (mg/dl) 1.29 0.73 1.3
eGFR (ml/min/1.73 m2) 64 32 6
Hemoglobin (g/dl) 12.5 1.8 12
hsCRP (mg/l) 12.7 25.3 7
Medication
Coumarins 28
ASA 62
Beta-blockers 86
ACE-I or ARB 85
Diuretics 80
Nitrates 24
Hydralazine 11
Aldosterone antagonists 29
Statins 60
Digoxin 41
AA drugs 17
Values are mean  SD or %.
AA  antiarrhythmic; ACE-I  angiotensin-converting enzyme inhib
B-type natriuretic peptide; BMI  body mass index; CABG  coronar
ejection fraction; eGFR  estimated glomerular filtration rate; hsCRP
 left bundle branch block; LVEF  left ventricular ejection fraction
end-systolic diameter; MR  mitral regurgitation; NYHA  New Yohere were significantly more super-responders in the LBBB nd QRSd 150 ms group (p  0.001) and significantly
ewer nonresponders in the 2 LBBB groups (p  0.001).
he change in MR was significantly less pronounced in
on-LBBB and QRSd 150 ms patients (MR actually
orsened [0.5  2.0]) compared with LBBB and QRSd
150 ms (p 0.001), and non-LBBB and QRSd150 ms
p  0.007) patients. In terms of clinical response, NYHA
lass improvement differed significantly between groups
p  0.001). More specifically, there was more improve-
ent in NYHA class in patients with LBBB and QRSd
d
0 ms
)
Non-LBBB and
QRSd >150 ms
(n  92)
Non-LBBB and
QRSd <150 ms
(n  103) p Value
0 67 13 67 11 0.001
84 84 0.0001
.3 29.2 6.3 29.6 6.4 0.54
.4 2.9 0.5 3.0 0.4 0.48
72 69 0.001
46 50 0.045
77 66 0.009
51 5 0.52
65 56 0.15
67 57 0.26
36 27 0.41
15 16 0.95
32 44 0.32
20 8 23 8 0.04
.1 6.6 0.9 6.2 1.1 0.002
.3 5.5 1.1 5.2 1.2 0.008
.3 3.7 2.5 3.3 2.2 0.44
34 584 696 596 713 0.87
.93 1.44 0.55 1.38 0.78 0.47
2 58 32 66 36 0.25
.8 12.8 2.1 12.5 2.0 0.53
.2 12.7 22.7 11.8 25.5 0.50
37 34 0.38
68 66 0.82
81 82 0.70
79 80 0.05
80 84 0.63
30 39 0.09
17 12 0.58
26 35 0.78
60 64 0.77
50 43 0.52
30 2 0.0005
B  angiotensin receptor blocker; ASA  acetylsalicylic acid; BNP 
bypass graft; COPD  chronic obstructive pulmonary disease; EF 
-sensitivity C-reactive protein; ICM  ischemic cardiomyopathy; LBBB
 left ventricular end-diastolic diameter; LVESD  left ventricular
t Association; QRSd  QRS duration.BB an
<15
 85
1 1
56
.8 6
.9 0
49
36
55
42
56
56
28
15
38
3 8
.0 1
.9 1
.8 2
4 7
8 0
7 4
.8 1
.2 8
29
63
85
71
76
30
12
30
56
48
8
itor; AR
y artery
 high150 ms compared with both non-LBBB groups (p  0.002
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CRT Response by QRS Morphology and Duration August 14, 2012:592–8vs. QRSd 150 ms and p  0.04 vs. QRSd 150 ms). In
a stepwise multivariate (linear) regression model (predicting
EF improvement), with baseline EF, LVEDD, atrial fibril-
lation, age, sex, diabetes mellitus, cardiomyopathy type, and
the 4 groups as candidate variables, the latter was the
strongest and first entered variable in the model
(p  0.0003). Interestingly, when QRS morphology and
QRSd were entered as separate candidate variables in a
stepwise model, QRSd was no longer significant (p 0.36).
Outcome data were completed for 478 patients (96%).
After a median follow-up of 5.2  0.9 years, 181 subjects
(38%) experienced the composite outcome; 171 deaths
(36%), 10 heart transplants (2%), and 2 underwent LVAD
placement (0.4%). The composite endpoint occurred in 31%
of the LBBB and QRS 150 ms group, 41% of the LBBB
and QRS150 ms group, 40% of the non-LBBB and QRS
150 ms group, and 48% of the non-LBBB and QRS
150 ms group (p 0.03). Figure 3 displays Kaplan-Meier
survival curves for the composite endpoint stratified accord-
ing to the 4 groups (log-rank test p  0.02). The specific
groups were significant predictors of the composite end-
point in a univariate Cox model (p  0.02). However, after
adjustment for other known predictors (sex, age, type of
cardiomyopathy, estimated glomerular filtration rate, and
EF), this was no longer significant (p  0.15) (Table 3).
Discussion
The key findings of this study can be summarized as follows:
1) non-LBBB, as the baseline ECG morphology before
CRT implantation, is much more prevalent in real-world
Echocardiographic and Clinical Response to CRTTable 2 Echocardiographic and Clinical Response to CRT
Response
LBBB and
QRSd >150 ms
(n  216)
LBBB
QRSd <
(n 
Echocardiographic response
EF pre (%) 21 8 23
EF post (%) 32 13 32
EF change (%) 12 12 8
LVEDD pre (cm) 6.2 1.0 6.0
LVEDD post (cm) 5.8 1.2 5.5
LVEDD change (cm) 0.45 0.95 0.26
LVESD pre (cm) 5.2 1.2 4.9
LVESD post (cm) 4.5 1.5 4.3
LVESD change (cm) 0.76 1.15 0.36
MR grades pre (1–9) 3.8 2.4 3.8
MR grades post (1–9) 3.1 2.5 3.4
MR grades change (1–9) 0.8 2.4 0.3
Super-responders 28 13
Negative responders 26 29
Clinical response
NYHA functional class pre 2.9 0.4 2.9
NYHA functional class post 2.0 0.6 2.0
NYHA functional class change 0.9 0.6 0.8
Values are mean  SD or %.
CRT  cardiac resynchronization therapy; other abbreviations as in Table1.practice than in randomized clinical trials; 2) echocardio-graphic and clinical response to CRT is determined by
baseline QRS morphology in the first place and to a lesser
degree by QRSd; 3) event-free survival (from death, heart
transplantation, or LVAD) is better in CRT-treated pa-
tients with baseline LBBB and QRS 150 ms. However,
this difference is not significant after adjusting for other
baseline characteristics.
From the early days of CRT, it was noticed that a
substantial subset of patients fail to benefit from this
treatment. Although this is in no way different from
s
Non-LBBB and
QRSd >150 ms
(n  92)
Non-LBBB and
QRSd <150 ms
(n  103) p Value
20 8 23 8 0.04
24 10 26 11 0.0001
5 9 3 11 0.0001
6.6 0.9 6.2 1.1 0.002
6.4 1.0 6.1 1.1 0.0002
0.29 0.57 0.02 0.81 0.007
5.5 1.1 5.2 1.2 0.008
5.2 1.1 5.0 1.1 0.0006
0.47 0.97 0.04 1.12 0.0005
3.7 2.5 3.3 2.2 0.44
2.6 1.9 3.5 2.3 0.25
1.0 2.3 0.5 2.0 0.001
9 10 0.001
47 51 0.001
2.9 0.5 3.0 0.4 0.48
2.3 0.6 2.4 0.6 0.0002
0.5 0.6 0.6 0.6 0.001
Figure 3 Survival After CRT Implantation
Kaplan-Meier curves for patients stratified into 4 groups according to baseline
QRS morphology and QRS duration. The outcome is the composite of death/
heart transplantation and left ventricular assist device placement. CRT  car-
diac resynchronization therapy.and
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August 14, 2012:592–8 CRT Response by QRS Morphology and Durationtreatment with medications, CRT has received considerable
attention because of the cost and invasive nature of this
therapy. Attempts to predict and subsequently minimize
nonresponders have focused on better patient selection by
analyzing data from subgroups of the original randomized
trials. Patients with non-LBBB morphologies, often under-
represented in clinical trials, or shorter QRSd on their
baseline ECG were repeatedly reported to gain less or even
no benefit. Stratifying patients, however, according to both
the morphology and the duration of the QRS complex has
been less frequently done (12,13). Nevertheless, we thought
this method was useful because it allows determining the
relative importance of these 2 electrocardiographic charac-
teristics. In addition, such classification mimics current
clinical thinking. The current results clearly stress the
importance of bundle branch type as the major electrocar-
diographic determinant of response to CRT. Patients with
a smaller QRS (120 to 149 ms) but LBBB morphology still
have a better echocardiographic and clinical response than
patients with a broad QRS (150 ms) but non-LBBB
morphology. In addition, multivariate modeling to predict
improvement in EF demonstrates the current classification
in 4 groups to be the most important factor in this
multivariate model. However, when QRS morphology and
QRSd were entered separately, only QRS morphology
stayed in the model. Taken together, our results reinforce
the importance of the presence of baseline dyssynchronous
LV activation as a prerequisite for response after CRT.
QRSd further expresses the extent of this dyssynchrony, and
the difference in echocardiographic response to CRT be-
tween patients with LBBB and QRSd 150 ms or 150
ms trended toward significance (p  0.12 with the conser-
vative Tukey test). Previous work from our group also
demonstrated the importance of QRSd within the non-
LBBB group as a predictor of echocardiographic response to
CRT (14). The findings in our study are in accordance with
those of a recent study by Gold et al. (15), emphasizing the
importance of LV activation delay. Thereby, a delay of 95 to
100 ms may be a significant predictor of CRT response.
Univariate and Multivariate Cox Proportional Hafor Death, Heart Transpl ntation, and Left VentrTable 3 Univa iate and Multiv riate Cox Profor Death, Heart Transplantation, an
Variable Unadjusted Hazard
QRS morphology/duration
LBBB and QRSd 150 ms 1.00
LBBB and QRSd 150 ms 1.46 (0.94–2.2
Non-LBBB and QRSd 150 ms 1.43 (0.95–2.1
Non-LBBB and QRSd 150 ms 1.80 (1.23–2.6
Male 2.28 (1.59–3.3
Age 70 yrs 1.16 (0.85–1.5
Ischemic cardiomyopathy 1.86 (1.35–2.5
eGFR 0.98 (0.98–0.9
Baseline EF 0.97 (0.95–0.9
Abbreviations as in Table 1.QRS configuration is a surface depiction of biventricular gactivation and may not specifically report inferolateral LV
conduction delay (16). In a previous study, significant LV
activation delay in patients with LV dysfunction was infre-
quent when QRSd was 150 ms but consistently high with
LBBB and QRSd 150 ms. However, similar QRSds in
roups with LBBB and RBBB and a wide QRS (164 ms)
oncealed very dissimilar LV activation delays. Fewer than
5% of patients with RBBB demonstrated delays equivalent
o those in patients with LBBB (17). Thus, the probability
istribution of LV activation delay according to QRS
orphology and QRSd may contribute to likelihood of
esponse to CRT.
There were no significant differences between the 4
roups in adjusted survival rates (free of death, heart
ransplantation, or LVAD insertion). Unadjusted, the group
ith the best response (LBBB patients with QRSd 150
s) had improved survival. These results have to be inter-
reted with caution. There are indeed some differences in
aseline characteristics (LBBB patients less often have
schemic cardiomyopathy and are more often female) that
ight explain that the adjusted survival difference is no
onger significant. However, it is important to realize that
he natural survival (without CRT) is worse for heart failure
atients with LBBB compared with RBBB or IVCD, as
hown in an Italian study and in a substudy of the MADIT-
RT trial (13,18). The latter study confirms (although the
urvival curves were unadjusted), in NYHA class I and II
atients, that the poorer prognosis associated with LBBB is
liminated with CRT treatment. Similarly, a recent analysis
f the Medicare registry demonstrated that RBBB was an
ndependent predictor of poor outcome in a CRT-treated
lderly population (12). Taken together, the division of CRT
atients according to branch block morphology and QRSd
learly and independently predicts CRT response. However, in
ur study, this division does not independently predict out-
ome anymore, which underscores the prognostic importance
f other demographic characteristics or comorbidities that are
nequally distributed in our 4 groups. In other words, the 4
Modelr Assist Device Placementonal Hazards Model
ft Ventricular Assist Device Placement
Cox Proportional Hazards
p Value Adjusted Hazard Ratio p Value
0.02 0.15
1.00
0.09 1.52 (0.95–2.38) 0.08
0.09 1.01 (0.65–1.55) 0.96
0.003 1.42 (0.93–2.15) 0.10
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CRT Response by QRS Morphology and Duration August 14, 2012:592–8Because of the lack of a control group without CRT, our
study cannot judge the potential clinical benefit of CRT nor
can it appreciate differences in treatment efficacy (less
benefit or even harm) between the 4 groups. However,
results of the MADIT-CRT substudy (which has a control
arm) suggest that there is no clinical benefit of CRT in
NYHA functional class I and II patients with non-LBBB,
both with QRSd150 ms and150 ms, despite significant
chocardiographic improvement in these subgroups (13).
tudy limitations. First, this was a retrospective study with
nherent imperfections in data collection or missing data.
or example, only 63% of patients had echocardiograms
vailable before and after CRT implantation. Patients with
issing echocardiogram data were more likely to have
on-LBBB with QRSd 150 ms and had worse survival. If
nything, this finding likely weakened the observed differ-
nces in echocardiographic response to CRT. Second, as a
ingle-center study, our patient cohort might be different
rom that in other centers. Third, the observed differences in
esponse to CRT are ascribed to differences in QRS
orphology and duration but could also be the result of
ther confounding differences between the groups. How-
ver, by controlling for the most frequent reported factors
nown to influence CRT response in a multivariate model,
e believe that the observed differences are indeed the result
f the different baseline electrocardiographic characteristics.
ourth, heart failure rehospitalization data were not col-
ected as an outcome parameter contrary to most random-
zed trials. Finally, it remains possible that there are sub-
roups within subgroups (e.g., RBBB vs. IVCD, male vs.
emale, ischemic vs. nonischemic) with different responses
o CRT. However, the number of patients was too small to
erform such analyses.
onclusions
y comparing QRS morphology and QRSd as baseline
haracteristics, we identified QRS morphology as the most
mportant predictor of response to CRT. Despite favorable
esponses in the LBBB groups, there were no statistically
ignificant differences in long-term outcomes among the
roups after adjustments, suggesting that comorbid condi-
ions may confound the treatment responses. Due to the
ack of sufficiently powered trials in these subgroups, guide-
ine committees have the difficult task of using this and
imilar studies to refine patient selection for CRT.
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